High-Dose Medroxyprogesterone Acetate (MPA) Treatment in Advanced Breast Cancer. A Review

@article{Ganzina1979HighDoseMA,
  title={High-Dose Medroxyprogesterone Acetate (MPA) Treatment in Advanced Breast Cancer. A Review},
  author={F. Ganzina},
  journal={Tumori Journal},
  year={1979},
  volume={65},
  pages={563 - 585}
}
Medroxyprogesterone acetate (MPA) when employed at high doses ≥ 500 ≤ 1000 mg/day i.m.) can produce objective remission with improved survival in about 30% of postmenopausal women with advanced breast cancer resistant to cytotoxic drugs and endocrine therapies. When administered to women not previously treated with chemotherapy, the objective remission response rate reached 40%. From available evidence, high dose MPA can be considered a useful agent in the treatment of advanced breast cancer in… Expand
Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer
Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer
Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
  • H. Muss, L. Case, +7 authors B. Powell
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1994
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 134 REFERENCES
MANAGEMENT OF ADVANCED ENDOMETRIAL ADENOCARCINOMA WITH MEDROXYPROGESTERONE ACETATE.
  • D. G. Anderson
  • Medicine
  • American journal of obstetrics and gynecology
  • 1965
High dose medroxyprogesterone-acetate treatment in advanced mammary carcinoma. A phase II investigation.
  • W. Mattsson
  • Medicine
  • Acta radiologica: oncology, radiation, physics, biology
  • 1978
Combined chemo‐ and hormonal therapy in advanced breast cancer
...
1
2
3
4
5
...